Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
暂无分享,去创建一个
A. Pappo | M. Devidas | M. Gebhardt | J. Jenkins | C. Pratt | H. Grier | R. Marcus | B. Rao | P. Thomas | B. Rao
[1] P. Thall,et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes , 2003, Statistics in medicine.
[2] C. Sawyers. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Merchant,et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Demetri,et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.
[5] T. Delaney,et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. , 2001, International journal of radiation oncology, biology, physics.
[6] G. Rosen,et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J W Oosterhuis,et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. , 2001, European journal of cancer.
[8] V. Bramwell,et al. Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft-Tissue Sarcoma: A Meta-Analysis and Clinical Practice Guideline , 2000, Sarcoma.
[9] T. Merchant,et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Merchant,et al. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children's Research Hospital experience. , 1999, Medical and pediatric oncology.
[11] A. Pappo,et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Green,et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. , 1998, Medical and pediatric oncology.
[13] R. Benjamin,et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Fletcher,et al. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Verweij,et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Rosen,et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide , 1994, Cancer.
[17] J. Crowley,et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Edmonson,et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Verweij,et al. Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. , 1992, Seminars in oncology.
[20] E. Gehan,et al. The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.
[21] R. Sylvester,et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. , 1987, European journal of cancer & clinical oncology.
[22] P. O'Brien,et al. Confidence intervals following group sequential tests. , 1986, Controlled clinical trials.
[23] J. Verweij,et al. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group , 2005, Journal of Cancer Research and Clinical Oncology.
[24] A. Pappo,et al. A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature. , 2003, Journal of pediatric hematology/oncology.
[25] O. S. Nielsen,et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2000, European journal of cancer.
[26] L. Ries,et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .
[27] M. van Glabbeke,et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Crowther,et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Verweij,et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. , 1993, Cancer chemotherapy and pharmacology.
[30] D. Crowther,et al. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. , 1993, Cancer chemotherapy and pharmacology.
[31] A. Elias,et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.